Impact of piflufolastat F‐18 PSMA PET imaging on clinical decision‐making in prostate cancer across disease states: A retrospective review
The Prostate · 2023
DOI: 10.1002/pros.24527 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Ali T Arafa und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Introduction
Piflufolastat F‐18 (18F‐DCFPyL) prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) imaging is approved by the US food and drug administration for initial staging of high‐risk prostate cancer, biochemical recurrence (BCR), and restaging of metastatic prostate cancer. Here, we sought to assess how its integration into clinical care may have impacted the management of patients.
Methods
We identified 235 consecutive patients who underwent an 18F‐DCFPyL PET scan from August 2021 to June 2022. The median prostate‐specific antigen at the time of imaging was 1.8 ng/mL (Range: 0−3740 ng/mL). Descriptive statistics were used to analyze its impact on clinical care for a subset of 157 patients with available treatment information: 22 for initial staging, 109 with BCR, and 26 patients with known metastatic disease.
Results
PSMA‐avid lesions were detected in 154/235 (65.5% of) patients. In patients undergoing initial staging, 18/39 (46.2% of) patients had extra‐prostatic metastatic lesions; 15/39 (38.5% of) scans were negative and 6/39 (15.4%) had equivocal results. 12/22 (54.5% of) patients had a change in their treatment plan post‐PSMA PET scan while 10/22 (45.5%) had no change in their treatment plan. In the BCR cohort, 93/150 (62.0%) had a local recurrence or metastatic lesions. Equivocal and negative scans accounted for 11/150 (7.3%) and 46/150 (30.7%) of scans, respectively. 37/109 (33.9% of) patients had a change in their treatment plan, while treatment was not altered in 72/109 (66.1% of) cases. In patients with metastatic disease, 43/46 (93.5%) had PSMA‐avid lesions identified; equivocal and negative scans accounted for 2/46 (4.3%) and 1/46 (2.2%) of scan results, respectively. 6/26 (23.1%) had their tentative treatment plan adjusted after the PSMA PET scan. No change in the treatment plan was observed in 20/26 (76.9% of) cases.
Conclusion
Integration of F‐18 PSMA PET imaging impacted clinical decision‐making and subsequent management across all stages of prostate cancer. It remains to be seen whether this translates into superior survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
- Thomayer Hospital, Charles University, Prague, Czech Republic.
- M Health Fairview University of Minnesota Medical Center Radiotheranostics Unit, Minneapolis, Minnesota, USA.
ORCID-Profile: Ali T Arafa, Emmanuel S Antonarakis
Zitieren
APA
Arafa, A. T., Jain, A., Skrobanek, P., Humphrey, B., Froelich, J. W., & Antonarakis, E. S. (2023). Impact of piflufolastat F‐18 PSMA PET imaging on clinical decision‐making in prostate cancer across disease states: A retrospective review. The Prostate. https://doi.org/10.1002/pros.24527
Vancouver
Arafa AT, Jain A, Skrobanek P, Humphrey B, Froelich JW, Antonarakis ES. Impact of piflufolastat F‐18 PSMA PET imaging on clinical decision‐making in prostate cancer across disease states: A retrospective review. The Prostate. 2023. doi:10.1002/pros.24527
BibTeX
@article{Arafa2023,
author = {Arafa, Ali T and Jain, Aditya and Skrobanek, Pavel and Humphrey, Brad and Froelich, Jerry W and Antonarakis, Emmanuel S},
title = {Impact of piflufolastat F‐18 PSMA PET imaging on clinical decision‐making in prostate cancer across disease states: A retrospective review},
journal = {The Prostate},
year = {2023},
doi = {10.1002/pros.24527}
}
EUVIMED